New endocrine agents, guidelines for future development
1989
Guidelines for Developing New Endocrine Cancer Treatments
Editorial
Author Information
Author(s): I.R. Judson
Primary Institution: Royal Marsden Hospital
Conclusion
The introduction of new endocrine agents for hormone-sensitive cancers could lead to better treatment options with fewer side effects.
Supporting Evidence
- Endocrine agents can have antitumor effects without significant toxicity.
- Tamoxifen has a low incidence of side effects and can be taken for long periods.
- New drugs must show high affinity for hormone receptors to be effective.
Takeaway
This article talks about how new medicines for cancer that depend on hormones can be made safer and more effective, which is good news for patients.
Methodology
The article discusses the need for specific guidelines in the development and testing of new endocrine agents for cancer treatment.
Potential Biases
Potential long-term side effects of endocrine treatments need to be considered.
Limitations
Current animal models for testing may not adequately represent post-menopausal breast cancer.
Want to read the original?
Access the complete publication on the publisher's website